Rendering of the Silkothane graft joining a red artery to a blue vein, with blood cells flowing through its three-layered silk wall

A vascular access for hemodialysis, spun from silk

The Silkothane® Arteriovenous Graft is now in its first-in-human clinical study in Italy.

Follow the clinical study
  1. SpunSilk fibroin from cocoons and medical-grade polyurethane, drawn into nano-fibres by electrospinning.
  2. LayeredWound into a three-layered, semi-resorbable wall, made to be ready off the shelf.
  3. ConnectedJoined between an artery and a vein, designed for dialysis within 48 hours.

How long a patient waits before the first needle

More than two million people depend on permanent dialysis, and each of them needs a vascular access that can be punctured three times a week, for years.

A native fistula needs 6 to 8 weeks to mature. Synthetic grafts are ready sooner, but too many lose patency or become infected. Dialybrid, based in Cantù near Como, is building a graft that brings the strengths of both together.

Native fistulamaturation, 6 to 8 weeks
Silkothane® graftdesign goal, within 48 hours
Ready for dialysis

From cocoon to vessel

Silkworm cocoons next to transparent polyurethane granules
Two materials, one graft. Silk fibroin for integration, medical-grade polyurethane for strength.

Silkothane®Silk fibroin from cocoons is combined with an implantable polycarbonate-urethane into a proprietary hybrid material.

First patient implanted in Varese

The first-in-human study of the Silkothane® Arteriovenous Graft as a hemodialysis access has started enrolling. The first patient was implanted by the coordinating principal investigator, Prof. Matteo Tozzi, Director of Vascular Surgery at ASST Sette Laghi and Professor at the University of Insubria.

Contact the clinical team
Device
Silkothane® Arteriovenous Graft, hybrid silk fibroin and polyurethane
Indication
Vascular access for patients with end-stage kidney disease who need hemodialysis
Enrolment
18 patients across four Italian sites
Follow-up
Data at 6, 12 and 24 months

Off the shelf

Ready for every patient, including frail elderly people whose own vessels are not suitable for a fistula.

Early cannulation

Designed for dialysis within 48 hours, compared with 6 to 8 weeks of maturation for a fistula.

Integration

Built for hemocompatibility and remodelling by host tissue, to address patency loss and infection.

News

  • Dialybrid secures a €15 million Series A led by XGEN Venture, with CDP Venture Capital

    Read
  • Successful first-in-human implant of the Silkothane® Arteriovenous Graft

    Read
  • Progress presented at the 5th Congress of the Vascular Access Society, Italian Chapter, San Giovanni Rotondo

    Read
Backed byXGEN VentureCDP Venture CapitalLIFTTComo VentureBioengineering Laboratories

Partners, investors and press are welcome to get in touch.

info@dialybrid.com

Dialybrid S.r.l.
Via Antonio Vivaldi 32/A
22063 Cantù (CO), Italy
+39 031 7377739